Vanguard Group’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Vanguard Group’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-556,423	Closed	-$1.77M	–	4663
2022 Q1	$1.77M	Sell	556,423 -23,438	-4%	-$67.4K	﹤0.01%	4004
2021 Q4	$1.66M	Buy	579,861 +243,274	+72%	+$906K	﹤0.01%	4107
2021 Q3	$1.34M	Hold	336,587	–	–	﹤0.01%	4179
2021 Q2	$2M	Sell	336,587 -39,424	-10%	-$279K	﹤0.01%	3966
2021 Q1	$4.57M	Buy	376,011 +247,324	+192%	+$3.52M	﹤0.01%	3578
2020 Q4	$1.88M	Buy	128,687 +65,769	+105%	+$838K	﹤0.01%	3678
2020 Q3	$724K	Buy	+62,918	New	+$806K	﹤0.01%	3736

Vanguard Group's CMPI Position: Q2 2022 in Review

Vanguard Group sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 556,423 shares — an estimated $1.77M sold.

Vanguard Group first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $4.57M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Vanguard Group reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Vanguard Group sold 556,423 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $1.77M.
Vanguard Group first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Vanguard Group's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $4.57M in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.